Culmerciclib

DRUG2 trials

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University, Fudan University

Conditions

Breast CancerHR+/HER2- Early Breast Cancer

Phase 2

Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer

RecruitingNCT07616453

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityHR+/HER2- Early Breast Cancer

Start: 2026-05-06End: 2033-05-05Target: 45Updated: 2026-06-01

A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.

RecruitingNCT07666555

Fudan UniversityBreast Cancer

Start: 2026-06-06End: 2029-12-30Target: 98Updated: 2026-06-24